Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Omega-3 wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Probably helps
18 of 27 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Noopept and Omega-3 have evidence — compare verdict strength side-by-side.
10-30mg daily in divided doses
Morning and early afternoon, Divided into 2-3 doses, Sublingual for faster onset
Noopept powder (sublingual) or capsules
2-3g combined EPA+DHA daily
With meals containing fat
Triglyceride form fish oil
1-2 weeks
Acute to 1 week
Ongoing
With higher doses
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
Novel Technologies for Dipeptide Drugs Design and their Implantation
Current pharmaceutical design (2018) · Systematic review
The latter usually corresponds to a beta-turn of some regulatory peptide.
Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation
Journal of biomedical science (2014) · Observational
Taken together, these data provide evidence that novel cognitive enhancer noopept protects PC12 cell against deleterious actions of Aβ through inhibiting the oxidative damage and calcium overload as well as suppressing the mitochondrial apoptotic pathway.
Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin
Neuroscience and behavioral physiology (2009) · Observational
Clinical trial examining Noopept efficacy
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
The present systematic review and meta-analysis indicate the efficacy of omega-3 FAs in increasing the serum concentration of BDNF.
Based on RCT with n=60 showing MMSE improvements after 2 months. Most studies lack placebo controls and have small sample sizes. Effectiveness may be overestimated due to study limitations.
Based on multiple meta-analyses showing EPA-dominant formulas >1g/day most effective. Effects plateau around 2-2.5g. Adjunctive use with antidepressants shows better outcomes than monotherapy.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 4/10) and wins in 3 of 3 categories.
For neuroprotection, Omega-3 has a higher relevance score (85 vs 65).
No known interactions between Noopept and Omega-3 have been documented in our database. However, always consult a healthcare provider before combining supplements.